ep figur prior figur
revenu figur prior figur
messag made modest chang non-
estim base increment detail model forecast provid manag
chang remain within guid rang present call februari
account increas jakafi product royalti revenu well
addit mileston payment base expect trial
initi psoriat arthriti also increas oper expens estim
full year high end compani guidanc rang
made sever adjust model increas estim
jakafi royalti revenu beyond estim increas
previous assum mileston payment
occur second quarter previous model though expect
record compani balanc sheet third quarter also slightli
increas estim jakafi sale addit expect
move forward trial psoriat arthriti thu account mileston
payment fourth quarter adjust non-gaap
revenu estim increas
pertain oper expens expect compani high end
guidanc rang previous provid manag earn call
increas expens estim increas sg
expens estim decreas estim stock
base compens beyond model approxim stock-bas
compens full year roughli sg
chang model net incom remain roughli full
year non-gaap net incom estim slightli decreas full year
valuat risk
valuat assum growth current jakafi sale ex-u royalti
myelofibrosi polycythemia vera baricitinib sale ra risk-adjust
epacadostat sale melanoma risk-adjust nsclc risk-adjust rcc
risk-adjust bladder cancer risk-adjust squamou cell head neck
cancer risk-adjust well iclusig sale take sum discount cash
flow use unchang risk-fre rate termin growth rate market premium
wacc plu net cash arriv pt
risk near-term risk rate price target includ limit
inci failur execut commerci jakafi unit state lower
expect ex-u jakafi royalti payment longer term key risk
includ unfavor clinical/regulatori outcom jakafi pancreat cancer baricitinib
 delay approv epacadostat plu keytruda melanoma
page analyst certif import disclosur
thousand except per-shar figur
licens royalti revenu
good sold
research develop
sell gener administr
incom loss oper
incom loss oper
royal taken product royalti revenu line
page analyst certif import disclosur
